Schechter Investment Advisors LLC Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schechter Investment Advisors LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 969 shares of the biopharmaceutical company’s stock after selling 13 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $851,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Sunbelt Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $25,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Sutton Wealth Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the period. Finally, Bruce G. Allen Investments LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $40,000. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by company insiders.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a “neutral” rating in a research note on Tuesday, February 6th. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Finally, BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $967.59.

Regeneron Pharmaceuticals Stock Up 0.3 %

REGN stock opened at $966.30 on Thursday. The company has a market cap of $106.06 billion, a price-to-earnings ratio of 27.81, a price-to-earnings-growth ratio of 2.77 and a beta of 0.11. The company has a fifty day moving average price of $957.54 and a 200 day moving average price of $878.93. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business posted $10.96 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.75 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.